Download PortFolio 01

Now More of Your Patients
Can Achieve Treatment Success
with Lantus2:
Almost 1% better A1C control compared to NPH
insulin without causing patients additional
hypoglycaemia1
The first and only once-daily, peakless insulin
analogue that provides 24-hours of complete
basal glucose control3
Continuous, predictable insulin release helps
patients reach target A1C ≤ 7%3
Less fluctuation means greater day-to-day
predictability—for more consistent control11
Once-daily, anytime dosing* can accommodate
most patient lifestyles and may improve
compliance3
*Can be administered any time of day, but must be given at the same time each day.